Xencor Inc: management transactions · United States · SEC (Form 4)

About Xencor Inc

Xencor Inc. (NASDAQ: XNCR) is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States. Headquartered in Pasadena, California, with additional operations in San Diego, the company focuses on antibody and protein engineering. Its core value proposition is the XmAb® technology platform, which is designed to modify the Fc domain of antibodies to improve function, extend half-life, or create new therapeutic mechanisms. That platform also supports advanced biologic formats such as bispecific antibodies. Founded in 1997, Xencor is closely tied to co-founder and Chief Executive Officer Bassil Dahiyat, Ph.D., who has led the company since incorporation. Over time, Xencor has built a business model that combines internal research and development with strategic partnerships and technology licensing. This approach has allowed the company to participate in the development of multiple partnered medicines while maintaining a pipeline of proprietary assets. For investors, that mix creates a hybrid profile: part innovation platform, part clinical-stage biotech, with revenue supported by collaboration activity rather than by marketed products of its own. Xencor’s operating focus is on engineered antibodies and cytokines for oncology and autoimmune disease, with a growing emphasis on inflammatory disease programs. The company states that more than 20 candidates engineered with its XmAb technology are in clinical development, and it highlights a portfolio of wholly owned clinical-stage programs. Recent attention has centered on assets targeting TL1A and on bispecific approaches for inflammatory bowel disease. In addition to proprietary programs, Xencor also benefits from partnered assets that have reached commercialization through larger biopharma collaborators, reinforcing the relevance of its platform beyond early discovery. Competitively, Xencor occupies a specialist niche rather than competing as a fully integrated pharmaceutical company. Its edge comes from deep protein engineering expertise, a strong intellectual-property base, and the ability to convert science into partnerships with larger industry players. This gives the company a way to access external capital and shared development economics while preserving upside in selected programs. At the same time, the company remains exposed to clinical and regulatory execution risk, which is typical for a development-stage biotech. Recent company updates have been focused on pipeline execution and 2026 milestones. In early 2026, Xencor outlined its corporate priorities and upcoming clinical catalysts, including progress for XmAb942 and plans for additional first-in-human work in its inflammatory disease portfolio. The latest financial communications also indicate a sizeable cash position and management’s expectation of funding runway through 2028 under current operating plans. For French-speaking investors tracking U.S. listed biotech names on NASDAQ, Xencor remains a science-driven story centered on platform value, partnership optionality, and clinical readouts.